COVID-19 Outcomes in Patients with Systemic Autoimmune Rheum
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Patients living with systemic autoimmune rheumatic diseases (SARDs) continue to be concerned about risks of severe COVID-19 outcomes.

A comparative cohort study of patients with SARDs diagnosed with COVID-19 (identified by diagnostic code or positive molecular test) versus non-SARD comparators with COVID-19, matched by age, sex, race/ethnicity, and body mass index (primary model) and comorbidities and health care utilization (extended model) was conducted.
-30 day outcomes were assessed, including hospitalization, (ICU) admission, mechanical ventilation, acute renal failure requiring renal replacement therapy (ARF), ischemic stroke, venous thromboembolism (VTE), and death.

Results:
--Initially 2,379 SARD patients with COVID-19 (mean age 58 years, 79% female) and 142,750 comparators (mean age 47 years, 54% female) were identified.
--In the primary matched model, SARD patients had significantly higher risks of hospitalization (RR 1.14), ICU admission (RR 1.32), ARF (RR 1.81), and VTE (RR 1.74) versus comparators but did not have significantly higher risks of mechanical ventilation or death.
--In the extended model, all risks were largely attenuated except risk of VTE (RR 1.60).

Conclusively, SARD patients with COVID-19 may be at higher risk of hospitalization, ICU admission, ARF, and VTE. These risks may be largely mediated by comorbidities, except for risk of VTE.

Source: https://onlinelibrary.wiley.com/doi/10.1002/art.41619
Like
Comment
Share